The supply of GLP-1 drugs has been increasing, but they’re still expensive for most patients. Here are answers to some ...

The stock's rise snapped a five-day losing streak.

Eli Lilly stock down 19% in May, on track for worst month since 2009. But June historically brings better fortune, with 67% ...

Eli Lilly's growth is impressive, but its current valuation is only justifiable with sustained high growth. Click here to ...

Johnson & Johnson's recent earnings beat expectations, with strong Medicine and MedTech growth. Read why I have a buy rating ...

CNBC’s Jim Cramer on Friday detailed how President Donald Trump’s global trade decisions seriously inhibit two of the U.S.’s biggest tech titans.

CNBC's Jim Cramer on Friday guided investors through next week on Wall Street, saying quarterly reports from Nvidia, Costco, Dell and Salesforce have the potential to move their respective sectors and ...

Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

HSBC has once again reduced its price target for Eli Lilly, this time dropping it to $675 from $700 while maintaining a ...

Contrarian investing advice from biotech and pharmaceutical stock expert Hartaj Singh, Founding Partner of Tecumseh Partners ...

The success of Eli Lilly & Co. 's weight-loss and diabetes drugs has pushed the company's stock to new heights, helping the ...